514 related articles for article (PubMed ID: 21885487)
21. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
[TBL] [Abstract][Full Text] [Related]
22. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
[TBL] [Abstract][Full Text] [Related]
23. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
24. Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis.
Eberhardt K; Sandqvist G; Geborek P
Scand J Rheumatol; 2008; 37(2):109-12. PubMed ID: 18415767
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
27. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM
Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526
[TBL] [Abstract][Full Text] [Related]
28. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
[TBL] [Abstract][Full Text] [Related]
29. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
31. Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies.
Paccou J; Solau-Gervais E; Houvenagel E; Salleron J; Luraschi H; Philippe P; Duquesnoy B; Flipo RM
Rheumatology (Oxford); 2011 Apr; 50(4):714-20. PubMed ID: 21131271
[TBL] [Abstract][Full Text] [Related]
32. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
33. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
[TBL] [Abstract][Full Text] [Related]
34. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
35. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
Van Doornum S; McColl G; Wicks IP
Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
[TBL] [Abstract][Full Text] [Related]
36. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.
DI Franco M; Paradiso M; Ceccarelli F; Scrivo R; Spinelli FR; Iannuccelli C; Valesini G
J Rheumatol; 2012 Jan; 39(1):41-5. PubMed ID: 22045840
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.
Bennett AN; Peterson P; Zain A; Grumley J; Panayi G; Kirkham B
Rheumatology (Oxford); 2005 Aug; 44(8):1026-31. PubMed ID: 15870150
[TBL] [Abstract][Full Text] [Related]
38. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
[TBL] [Abstract][Full Text] [Related]
39. Switching between anti-TNF-alpha agents does not improve functional capacity in patients with long-standing and active rheumatoid arthritis.
Soares MR; Reis Neto ET; Luz KR; Ciconelli RM; Pinheiro MM
Rev Bras Reumatol; 2012; 52(1):9-15. PubMed ID: 22286641
[TBL] [Abstract][Full Text] [Related]
40. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
Bilgen SA; Kilic L; Akdogan A; Kiraz S; Kalyoncu U; Karadag O; Ertenli I; Dogan I; Calguneri M
J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
